SOURCE: Ablynx

October 30, 2009 13:10 ET


GHENT, BELGIUM--(Marketwire - October 30, 2009) - Ablynx [Euronext Brussels: ABLX] today announced that an additional 4,407 common shares have been issued by the Company in exchange for EUR 6,732.60 as the result of the exercise of warrants by some employees and consultants of the Company.

As a result of this transaction, Ablynx now has 36,889,789 shares outstanding.


About Ablynx [Euronext Brussels: ABLX] - Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 220 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007.

Ablynx is developing a portfolio of Nanobody®-based therapeutics in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Nanobodies® have been generated against more than 150 different disease targets. Efficacy data have been obtained in over 26 in vivo models for Nanobodies® against a range of different targets.

Ablynx has an extensive patent position in the field of Nanobodies® for healthcare applications. It has exclusive and worldwide rights to more than 50 families of granted patents and pending patent applications, including the Hamers patents covering the basic structure, composition, preparation and uses of Nanobodies®.

Ablynx has ongoing research collaborations and significant partnerships with several major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Wyeth Pharmaceuticals. Ablynx is building a diverse and broad portfolio of therapeutic Nanobodies® through these collaborations as well as through its own internal discovery programmes.

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.

Contact Information

  • For more information, please contact:

    College Hill Life Sciences - for International media enquiries:
    Sue Charles, Justine Lamond, Dr John McIntyre
    t: +44 (0)20 7866 7857

    Dr. Edwin Moses
    Chairman and CEO
    t: +32 (0)9 262 00 07
    m: +44 (0)7771 954 193 / +32 (0)473 39 50 68

    Eva-Lotta Allan
    Chief Business Officer
    t: +32 (0)9 262 00 75
    m: +32 (0)475 78 36 21 / +44 (0)7990 570 900

    Wim Ottevaere
    Chief Financial Officer
    t: +32 (0)9 262 00 11